GP方案与NP方案治疗蒽环类及紫杉类耐药晚期乳腺癌的疗效观察

Clinical observation of GP and NP regimen in treating advanced breast cancer patients with anthracycline and taxane resistantace

目的:观察吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的近期疗效及不良反应。方法:将接受蒽环类及紫杉类药物治疗失败的45例晚期乳腺癌患者随机分组,GP方案组22例,NP方案组23例,化疗2周期后评价疗效。结果:GP组与NP组总有效率分别为40.9%和43.5%,疾病控制率分别为72.7%与69.6%,1年生存率分别为54.5%与52.2%,两组比较差异无显著性(P>0.05)。主要不良反应为骨髓抑制及消化道反应,两组比较差异无显著性(P>0.05)。结论:GP方案与NP方案治疗蒽环类及紫杉类耐药的晚期乳腺癌近期疗效肯定,不良反应可耐受。

Objective：To observe the effect and toxicities of gemcitabine plus cisplatin （GP） regimen and vinorelbine plus cisplatin （NP） regimen in treating advanced breast cancer patients with anthracycline and taxane resistantace. Methods： We randomly divided 45 patients with advanced breast cancer treated failure by anthracycline and taxane into two groups ,22 patients treated by GP and 23 patients treated by NP. To evaluate the chemotherapy effect after 2 cycles. Results： The total effective rate were 40.9% and 43.5% in GP group and NP group, the disease control rates were 72.7% and 69.6%, 1 year survival rates were 54.5% and 52.2% ,the difference between the two groups was not significant （P 〉 0.05 ）. The main toxicities were bone marrow depression and gastrointestinal reaction, two groups had no significant differences （ P 〉 0.05 ）. Conclusion： The curative effect and side effects of GP and NP regimens in treating advanced breast cancer patients with anthracycline and taxane resistantace are similar.